Genetic Variants in Thyroid Cancer Distant Metastases

Steven E. Justiniano¹, Joseph P. McElroy², Lianbo Yu², Ayse Selen Yilmaz², Kevin R. Coombes², Leigha Senter³, Rebecca Nagy³,⁷, Paul Wakely, Jr⁴, Stefano Volinia⁵, Michelle Vinco⁸, Thomas J. Giordano⁸,⁹, Carlo M. Croce⁶, Motoyasu Saji¹, Matthew D. Ringel¹,⁸

¹ Division of Endocrinology, Diabetes, and Metabolism, ²Center for Biostatistics and Department of Bioinformatics; ³Division of Human Genetics, ⁴Department of Pathology; ⁵Department of Morphology, Surgery and Experimental Medicine, University of Ferrara, Italy, ⁶Department of Molecular Virology, Immunology, and Genetics, The Ohio State University Wexner Medical Center and Arthur G. James Comprehensive Cancer Center, Columbus OH; ⁷Guardant Health, Inc, Redwood City, CA; ⁸Department of Pathology, University of Michigan, Ann Arbor, MI; ⁹Comprehensive Cancer Center, University of Michigan, Ann Arbor, MI

Address for Correspondence:
Matthew D. Ringel, MD
565 McCambpell Hall; 1581 Dodd Drive
Columbus, OH 43210

Email: matthew.ringel@osumc.edu
Tel: 614-685-3333  Fax: 614-685-3335
Dear Editor:

Thyroid carcinoma is the most rapidly increasing solid tumor in the United States, and while there has been great emphasis on the analysis of primary tumors, predictors of both late stage progression and response to therapy are more poorly defined due in part to scarcity of progressive metastatic tissues. Therapeutic evidence of mixed responses in metastatic lesions, and the limited available genomic data suggest that distant metastases in thyroid cancer are heterogeneous, driven by known oncogenes and other pathways that also might be therapeutic targets. We analyzed the genomes of a small number of rare surgically resected metastatic thyroid cancer lesions along paired normal and primary tumor samples when available, in an effort to better characterize progressive distant metastases. The findings confirm the presence of mutations to known tumor drivers (BRAF and RAS) in metastatic samples. The results also identified co-occurrence in predicted functional variants to the DNA damage repair (DDR) genes ATM and ERCC4 in metastatic lesions that did not show alterations of the MAPK pathway.

We examined the exomes of 19 samples (including 5 paired normal tissues) from 11 follicular cell-derived thyroid cancer patients with surgically resected distant metastases by custom exomeSeq (Supplement). Tumors with different histopathologies were included and were confirmed by an expert thyroid pathologist (PW). All patients were treated with TSH suppression, eight received I-131 therapy, and none received chemotherapy or kinase inhibitors. 19,299 unique variants in the 682 genes and genomic regions were identified by an exomeSeq custom panel. We sought to identify rare, conserved, exonic variants that were likely to have functional effects. Thus, we focused on 1,742 exonic variants in exons of sequenced genes. We excluded synonymous variants and variants with higher than 0.01 Minor Allelic Frequency in the 1000 Genomes Project. We then filtered to include variants located in regions that were conserved through vertebrate evolution. These criteria produced a list of 349 variants in 199 genes. Unsupervised clustering using complete linkage and Euclidian distance identified clusters based on patients, suggesting that most variants were primarily associated with individuals rather than histology or tissue location (data not shown). We finally applied a filter to identify variants predicted or known to have a damaging (SIFT) or deleterious (Polyphen) effect on the protein. Figure 1 summarizes the filtering strategy.

In the primary tumors of patients with distant metastases, 33 variants in 31 genes were identified by comparison to normal samples. We focused on genes affected in more than one tumor sample and found three such genes: BCR, BRAF and MAP4 (Figure 2). Two variants that affect BRAF in five primary tumor samples were identified. A Hürthle cell carcinoma (HCC) bore a BRAF T241M variant, although its functional significance is uncertain. The remaining samples with BRAF had mutations resulting in BRAF V600E and included two papillary thyroid cancers (PTC) primary tumors and a metastatic lesion, and one anaplastic thyroid cancer (ATC) metastatic lesion. We also identified four samples from four patients with an identical insertion resulting in a frameshift (chr22:23653975 Indel: TCCGG) in BCR including three primary tumors and one metastasis. The primary tumor samples were from follicular (FTC) and HCC, and a metastatic lesion from BRAF V600E PTC. Finally, three primary tumors had an identical mutation (R1112P) in MAP4. Two of the tumors are from patients with HCC, and the third is a PTC with a concurrent BRAFV600E mutation. BCR and MAP4 are functionally involved in
cytoskeletal dynamics, although those roles and functional implications of the variants identified are not completely characterized.

In the metastatic tissues we identified thirty variants in twenty-eight genes after filtering that were unique vs normal tissues. Variants in three genes, \textit{ATM}, \textit{BRAF}, and \textit{ERCC4} were present in more than one sample (\textit{Figure 2}). There were two variants and a deletion in \textit{ATM} distributed among five samples from four patients. Variant CHR11:108236086 results in a R3008C transition was found in a primary tumor and metastatic lesion, but not matched normal tissue. Variant CHR11:108236153 resulting in a G3030E was found in three samples from three different patients. Both \textit{ATM} variants occur in the C-terminal FATC domain of the protein. We also identified a deletion in \textit{ATM} resulting in a frameshift. Additionally, we identified two variants in the \textit{ERCC4}/\textit{XPF} tumor suppressor gene. Variant CHR16:14041714 was found in a metastatic lesion from HCC and was concurrent with \textit{ATM} variant CHR11:108236086. The second variant as identified in two metastatic samples from two patients and is concurrent with \textit{ATM} variant CHR11:108236153.

We compared our results in primary tumors to those of the TCGA project on differentiated PTC (Cancer Genome Atlas Research Network 2014). Approximately 60% of TCGA samples have a \textit{BRAF V600E} mutation and 13.5% \textit{RAS} mutation. In contrast our study found \textit{BRAF V600E} in four samples and four samples with a \textit{RAS} mutation among primary tumor and metastatic lesion samples. Although these differences may be due to the variety of histological types examined, a recent study focusing on poorly differentiated and anaplastic thyroid cancers (Landa, et al. 2016) reported a similar rate of \textit{BRAF V600E} (~33%), and \textit{RAS} (~27%).

Interestingly, five samples in the present study had variants in the \textit{ATM} tumor suppressor. In TCGA, only 1.3% of the differentiated PTC harbored variants in this gene, and none of those were located in the FATC domain. \textit{ATM} mutations were reported by Landa and colleagues in 9% of samples, although none were located in the FATC domain. In that study four \textit{ATM} samples were concurrent with \textit{BRAF V600E}, and one sample had concurrent \textit{ATM} and \textit{NRAS Q61R} variants. Additional examination of publically available tissues (COSMIC) allowed us to identify 92 tumors and cell lines containing mutations of the \textit{ATM} FATC domain. Five of those samples have concurrent \textit{BRAF} mutations, but only two were \textit{BRAF V600E}, one colon adenocarcinoma and one malignant melanoma. The FATC domain of ATM has been reported to be critical for telomere maintenance and effective DDR (Ogi, et al. 2015). Additionally, the FATC domain has been implicated in \textit{NOTCH1} regulation and leukemia cell survival (Vermezovic, et al. 2015). Codon 3008 appears to be a mutation hotspot, and this variant has been shown to have a dominant negative effect \textit{in vitro} (Meyn 1999). The relationship between \textit{BRAF V600E} and \textit{ATM} FATC domain variants may suggest redundant functions that would require experimental verification.

We also identified variants in the a second gene involved in the DDR, \textit{ERCC4}/\textit{XPF} exclusively in metastatic samples and only in co-occurrence with \textit{ATM} FATC variants. Altered expression of \textit{ERCC4} is common in colon cancer, where ~55% of cases have epigenetic repression of the gene (Facista, et al. 2012). While it is not clear that \textit{ATM} and \textit{ERCC4}
cooperate in thyrocytes, such an interaction has been suggested in CLL cells in which cooccurrence of mutations in ERCC4 and ATM predicted synthetic lethality to ATR kinase inhibitors (Kwok, et al. 2016).

The PTC TCGA study identified DDR variants in ~6.5% of samples, and no case had mutations to multiple DDR components (Cancer Genome Atlas Research Network 2014). In contrast, Landa and colleagues reported in poorly differentiated tumors that 38% of samples contain a mutation in at least one DDR genes, most commonly TP53, and in ~6% of cases there were mutations to multiple DDR genes (Landa et al. 2016). A recent study (Sohn, et al. 2016) analyzed distant metastases and primary tumors from a group of well-differentiated PTC and FTCs using a targeted gene panel. That study found BRAF and RAS mutations were largely conserved between primary tumors and distant metastases, but did not identify ATM variants or examine ERCC4/XPF as part of the panel. In the present study, the ATM and ERCC4 variants occurred in an FTC, HCC or ATC tumors, while none were noted in PTC samples. Finally, due to its relevance in thyroid cancer, we examined primary tumor samples from four (10, 12, UM2 & UM4) patients with adequate residual DNA for TERT promoter mutations by Sanger sequencing. One C228T mutation was identified (UM4) which did not have a variant in ERCC4 or a FATC domain variant in ATM. These data suggest that mutations in DDR-related genes may be enriched in poorly differentiated and non-PTC progressive metastatic thyroid cancers, although the small samples size of this study requires further work to test this hypothesis.

It is important to note that these findings are in a small number of samples from a diverse group of tumors and require confirmation to rule out false positive results. Moreover, the use of a broader high density sequencing platforms may lead to additional findings and functional studies are needed for variants of uncertain functional significance. We believe these descriptive data provide a scaffold for further studies to better define therapeutic targets for patients with progressive metastatic thyroid cancer.
Declaration of interest: The authors declare that there is no conflict of interest that could be perceived as prejudicing the impartiality of the research reported.

Funding: This research was supported by NIH grant to MDR (P01 CA124570 and P50CA168505) and an S grant to SV from AIRC (Associazione Italiana per la Ricerca sul Cancro).

Figure Legends

Figure 1. Schematic of the filtering criteria used on the genomic data to identify genes mutated in pathological samples. Five genes met an additional requirement that the gene had to be present in more than one sample.

Figure 2. Candidate genes & variants found uniquely in more than one of 14 tumor tissue samples (primary or metastatic) vs normal tissues following filtering. One sample did not include a mutation in any of the analyzed genes.
References


Sohn SY, Park WY, Shin HT, Bae JS, Ki CS, Oh YL, Kim SW & Chung JH 2016 Highly Concordant Key Genetic Alterations in Primary Tumors and Matched Distant Metastases in Differentiated Thyroid Cancer. *Thyroid* **26** 672-682.

Figure 1

682 genomic features
13535 variants

GRCh37 Hg19
Exons only
1742 variants

1000 genomes & PhyloP/SipPhy
Rare & conserved
349 variants

Exclude if present in normal
Tumor R56 variants or Metastatic lesion 82 variants

SIFT or Polyphen
Variant(s) in this gene(s) are present in more than one sample (Primary tumor/Metastatic lesion)

Braf (2/2)
MAP4 (3/0)
BCR (3/1)
ATM (1/3)
ERCC4 (0/3)
Figure 2

16x11mm (600 x 600 DPI)